Effect of polyclonal activators on cytokine production by blood cells and by malignant breast cancer cells

Кунц, Т. А.; Карпухина, К. В.; Mikhaylova, E. S.; Маринкин, И. О.; Вараксин, Н. А.; Autenshlyus, A. I.; Lyakhovich, V. V.

doi:10.1134/s0012496616010026

Cited by 2 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Contrarily, literature demonstrated IL-18 as a pro-oncogenic cytokine (Ref. 75) where its expression in BC led to enhanced invasion, metastasis (Refs 76, 77, 78, 79, 80, 81), migration (Refs 76, 82), proliferation (Ref. 83), angiogenesis (Ref.…”

Section: What Are Inflammasomes?mentioning

confidence: 99%

Inflammasomes in breast cancer: the ignition spark of progression and resistance?

Elgohary

Tayebi

2023

Expert Rev. Mol. Med.

View full text Add to dashboard Cite

Inflammation and immune evasion are major key players in breast cancer (BC) progression. Recently, the FDA approved the use of anti-programmed death-ligand 1 antibody (anti-PD-L1) and phosphoinositide 3-kinase (PI3K) inhibitors against aggressive BC. Despite the paradigm shift in BC treatments, patients still suffer from resistance, recurrence and serious immune-related adverse events. These obstacles require unravelling of the hidden molecular contributors for such therapy failure hence yielding therapeutics that are at least as efficient yet safer. Inflammasome pathway is activated when the pattern recognition receptor senses danger signals (danger-associated molecular patterns) from damagedRdying cells or pathogen-associated molecular patterns found in microbes, leading to secretion of the active pro-inflammatory cytokines interleukin-1β (IL-1β) and interleukin-18 (IL-18). It has been shown throughout numerous studies that inflammasome pathway enhanced invasion, metastasis, provoked BC progression and therapy resistance. Additionally, inflammasomes upregulated the proliferative index ki67 and enhanced PD-L1 expression leading to immunotherapy resistance. IL-1β contributed to significant decrease in oestrogen receptor levels and promoted BC chemo-resistance. High levels of IL-18 in sera of BC patients were associated with worst prognosis. Stimulation of purinergic receptors and modulation of adipokines in obese subjects activated inflammasomes that evoked radiotherapy resistance and BC progression. The micro RNA miR-223-3p attenuated the inflammasome over-expression leading to lowered tumour volume and lessened angiogenesis in BC. This review sheds the light on the molecular pathways of inflammasomes and their impacts in distinct BC subtypes. In addition, it highlights novel strategies in treatment and prevention of BC.

show abstract

Section: What Are Inflammasomes?mentioning

confidence: 99%

Inflammasomes in breast cancer: the ignition spark of progression and resistance?

Elgohary

Tayebi

2023

Expert Rev. Mol. Med.

View full text Add to dashboard Cite

show abstract

Cytokine production by the tumor from patients with breast cancer in different age groups

et al. 2017

View full text Add to dashboard Cite

Dependence of cytokine pattern in the tumor supernatant obtained after cultivation of biopsy samples-on the patients' age was evaluated among patients with invasive ductal carcinoma of the breast. An increase in VEGF and IL-6 production in a group of younger patients was observed. An increase only in interferon γ concentration was revealed in the supernatants of the tumor after addition of polyclonal activators to the culture medium. This result indicates likely secretion of interferon γ in younger patients. The relation among the production of angiogenic factors by tumor cells, age of the patients, and presence or absence of lymph node metastases shows that in such studies, patients have to be stratified by age.

show abstract

Effect of polyclonal activators on cytokine production by blood cells and by malignant breast cancer cells

Cited by 2 publications

References 10 publications

Inflammasomes in breast cancer: the ignition spark of progression and resistance?

Inflammasomes in breast cancer: the ignition spark of progression and resistance?

Cytokine production by the tumor from patients with breast cancer in different age groups

Contact Info

Product

Resources

About